Close Menu

NEW YORK – Adaptive Biotechnologies this week announced the closing of its initial public offering of 15 million shares of common stock and the exercise in full of the underwriters' option to purchase 2.25 million additional shares at a public offering price of $20 per share. Gross proceeds from the offering were approximately $345 million before deducting underwriting discounts and commissions and estimated offering expenses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.